On November 17, a Type A meeting was held with the FDA to discuss the review of the Biologics License Application for remestemcel-L and a potential pathway for accelerated approval with a post-approval requirement to conduct an additional randomized controlled study in patients 12 years and older. At the current time it appears that the FDA review team will not agree to accelerated approval. However, the definitive outcome of the Type A meeting will not be known until Mesoblast receives the formal minutes which are expected within 30 days of the meeting
- Forums
- ASX - By Stock
- MSB
- Ann: MSB Q1 Financial Results and Operational Highlights
Ann: MSB Q1 Financial Results and Operational Highlights, page-9
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
97.0¢ | $1.01 | 96.5¢ | $7.757M | 7.884M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 274918 | 97.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 974 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 103162 | 0.970 |
5 | 34741 | 0.965 |
11 | 125566 | 0.960 |
1 | 500 | 0.955 |
22 | 165429 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 974 | 1 |
0.990 | 10204 | 1 |
1.000 | 14000 | 1 |
1.010 | 2877 | 1 |
1.015 | 60000 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |